Rosuvastatin protects tissue perfusion in the experimental testicular torsion model.
Recently, anti-inflammatory and tissue protective effects of statins have been shown independent from its anti-hyperlipidemic effect. It has been shown that one of the statins, rosuvastatin, may reduce ischemia/reperfusion (I/R)-induced tissue injury in the brain, intestines, and heart. We planned an experimental study to evaluate the effect of rosuvastatin on I/R injury encountered after the detorsion of the testicular torsion. Rats were divided into three groups. In group 1, testis basal blood flow (basal value) was measured with LASER Doppler flowmeter (LDF). Testis was relocated into the scrotum without torsion. Two and 3 h after the basal measurement, testis was brought out from the same incision, and the second (second value) and third (third value) testicular blood flow measurements were done, respectively. In group 2, after the measurement of basal value testicular torsion was created. Second and third value measurements were obtained with LDF at the end of the 2 h of testicular torsion just before the detorsion and 1 h after detorsion. In group 3, same procedures in torsion/detorsion group were repeated in this group, but 10 mg/kg rosuvastatin was injected intraperitoneally 30 min before detorsion. Second values in groups 2 and 3 were significantly lower than group 1. Third values were significantly low in group 2 compared to groups 1 and 3. Regarding the third measurement, there was no significant difference between the groups 1 and 3. Tissue injury is closely related with condition of microvascular perfusion after I/R. Rosuvastatin can protect tissue perfusion in the experimental testicular torsion model.
Karakaya
Erdal
E
Department of Pediatric Surgery, School of Medicine, Dokuz Eylül University, Balçova, Izmir, Turkey.
Ateş
Oğuz
O
Akgür
Feza M
FM
Olguner
Mustafa
M
D000818:Animals; D004195:Disease Models, Animal; D005464:Fluorobenzenes / Q000627:therapeutic use*; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D011743:Pyrimidines / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000209:etiology* / Q000517:prevention & control*; D000068718:Rosuvastatin Calcium; D013086:Spermatic Cord Torsion / Q000150:complications*; D013449:Sulfonamides / Q000627:therapeutic use*
D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium
J Urol. 1994 Jun;151(6):1715-7
8189603
BJU Int. 2005 Jul;96(1):175-80
15963144
Neuroscience. 2005;134(3):901-6
16009498
Brain Res. 2002 Jun 28;942(1-2):23-30
12031849
Urol Res. 1993;21(6):395-9
8171761
World J Gastroenterol. 2006 Apr 7;12(13):2024-30
16610051
J Pediatr Surg. 2004 Aug;39(8):1238-41
15300535
Eur Urol. 1998;33(6):576-80
9743701
Am J Physiol Heart Circ Physiol. 2005 Apr;288(4):H1802-9
15563531
J Surg Res. 2006 Apr;131(2):199-203
16412470
J Pediatr Surg. 2003 Nov;38(11):1621-7
14614712
Arterioscler Thromb Vasc Biol. 2005 May;25(5):1071-7
15761193
Pediatr Surg Int. 2003 Jul;19(5):395-9
12783260
Br J Pharmacol. 2001 Jun;133(3):406-12
11375257
Int Urol Nephrol. 2002;34(1):81-6
12549645
J Am Coll Cardiol. 2002 Sep 18;40(6):1172-8
12354446
Int J Mol Med. 2006 Jun;17(6):997-1004
16685407
J Urol. 1997 Sep;158(3 Pt 2):1138-40
9258157
Urology. 1994 Sep;44(3):413-8
8073557
Atheroscler Suppl. 2006 Apr;7(1):31-5
16503422
Stroke. 2005 Feb;36(2):332-6
15625301
Shock. 1997 Jul;8(1):2-7
9249906
Urology. 2005 Dec;66(6):1338-42
16360480